Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

BACKGROUND: The recently published cardiovascular outcomes data for the first sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower...

Descripción completa

Detalles Bibliográficos
Autores principales: Ampudia-Blasco, Francisco Javier, Romera, Irene, Ariño, Bernat, Gomis, Ramón
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245975/
https://www.ncbi.nlm.nih.gov/pubmed/28144158
http://dx.doi.org/10.2147/IJGM.S115566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245975/
https://www.ncbi.nlm.nih.gov/pubmed/28144158
http://dx.doi.org/10.2147/IJGM.S115566

Ejemplares similares